MedTrace Logo

Impact of Triple Combination CFTR Therapy on Sinus Disease.

NCT04056702 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2021-03-11

No results posted yet for this study

Summary

The study's main goal is to observe how effective elexacaftor-tezacaftor-ivacaftor is for improving the symptoms and signs of CF-related sinus disease.

Conditions

Interventions

DRUG

Elexacaftor-tezacaftor-ivacaftor exposure

Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.

Sponsors & Collaborators

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • Jennifer Taylor-Cousar

    lead OTHER

Principal Investigators

  • Jennifer TaylorCousar, M.D. · National Jewish Health

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2021-07-31
Completion
2022-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04056702 on ClinicalTrials.gov